| Symbol | BLTE |
|---|---|
| Name | BELITE BIO, INC |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 5820 OBERLIN DRIVE,SUITE 101, SAN DIEGO, California, 92121, United States |
| Telephone | +1 858 246-6240 |
| Fax | — |
| — | |
| Website | https://www.belitebio.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001889109 |
| Description | Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout. Additional info from NASDAQ: |
Lin Yu-Hsin 🔴 sold 100.4K shares of BELITE BIO, INC (BLTE) at $198.09 ($19.1M) Transaction Date: Sep 04, 2026 | Filing ID: 386794
Read moreChuang Hao-Yuan 🔴 sold 67.4K shares of BELITE BIO, INC (BLTE) at $198.05 ($12.8M) Transaction Date: Sep 04, 2026 | Filing ID: 386790
Read moreBelite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1
Read moreBelite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
Read moreChuang Hao-Yuan 🔴 sold 367 shares of BELITE BIO, INC (BLTE) at $180.57 Transaction Date: Aug 12, 2026 | Filing ID: 350218
Read moreLin Yu-Hsin 🔴 sold 365 shares of BELITE BIO, INC (BLTE) at $180.57 Transaction Date: Aug 12, 2026 | Filing ID: 350217
Read moreBelite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update
Read more📋 Yu-Hsin Lin (CEO, Chairman) plans to sell 127K shares of Belite Bio, Inc. (at $177.58 each, total $22.5M) Filed: Aug 12, 2026 | ID: 000825
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06388083 | A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subject… | Phase2 | STGD1 | Active_Not_Recruiting | 2024-07-31 | 2028-02-01 | ClinicalTrials.gov |
| NCT05949593 | Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety … | Phase3 | Geographic Atrophy | Active_Not_Recruiting | 2023-07-27 | 2027-08-31 | ClinicalTrials.gov |
| NCT05667688 | Pharmacokinetics and Pharmacodynamics Study of LBS-008 in Healthy Volunteers Ag… | Phase1 | Healthy Volunteer | Completed | 2022-11-28 | 2023-01-18 | ClinicalTrials.gov |
| NCT05244304 | Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety … | Phase3 | Stargardt Disease 1 | Completed | 2022-03-28 | 2025-09-11 | ClinicalTrials.gov |
| NCT05266014 | This is a Dose-finding Study Followed by 2-year Extension Study to Evaluate Saf… | Phase1 | Stargardt Disease | Completed | 2021-03-12 | 2023-08-15 | ClinicalTrials.gov |
| NCT04005807 | Safety and Tolerability of Escalating Doses of BPN-14967 in Healthy Adults | Phase1 | Healthy Volunteers | Completed | 2019-07-19 | 2019-12-20 | ClinicalTrials.gov |
| NCT03735810 | Safety and Tolerability Study of LBS-008 in Healthy Adult Subjects After Single… | Phase1 | Healthy Volunteer | Completed | 2018-11-15 | 2019-09-16 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE3 | Stargardt Disease 1 | COMPLETED | NCT05244304 |
| Tinlarebant | Other | Phase PHASE3 | Stargardt Disease 1 | COMPLETED | NCT05244304 |
| Placebo | Other | Phase PHASE3 | Stargardt Disease 1 | COMPLETED | NCT05244304 |
| Tinlarebant | Other | Phase PHASE3 | Stargardt Disease 1 | COMPLETED | NCT05244304 |
| Placebos | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT03735810 |
| LBS-008 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT03735810 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04005807 |
| BPN-14967 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04005807 |
| Tinlarebant (LBS-008) | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05667688 |
| tinlarebant | Other | Phase PHASE1 | Stargardt Disease | COMPLETED | NCT05266014 |
| Placebo | Other | Phase PHASE3 | Geographic Atrophy | ACTIVE_NOT_RECRUITING | NCT05949593 |
| Tinlarebant | Other | Phase PHASE3 | Geographic Atrophy | ACTIVE_NOT_RECRUITING | NCT05949593 |
| Placebo | Other | Phase PHASE2 | STGD1 | ACTIVE_NOT_RECRUITING | NCT06388083 |
| Tinlarebant | Other | Phase PHASE2 | STGD1 | ACTIVE_NOT_RECRUITING | NCT06388083 |
| Tinlarebant (LBS-008) | DRUG | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05667688 |
| tinlarebant | DRUG | Phase PHASE1 | Stargardt Disease | COMPLETED | NCT05266014 |
| Tinlarebant | DRUG | Phase PHASE2 | STGD1 | ACTIVE_NOT_RECRUITING | NCT06388083 |
| Placebo | DRUG | Phase PHASE2 | STGD1 | ACTIVE_NOT_RECRUITING | NCT06388083 |
| BPN-14967 | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04005807 |
| Placebos | DRUG | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT03735810 |
| LBS-008 | DRUG | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT03735810 |